Benzinga | Jun 21, 2021 10:28AM EDT

Auris Medical Stock Trading Higher After OligoPhore Technology Shows Tumor Inhibition In Animal Studies

* Auris Medical Holding Ltd (NASDAQ:EARS) has announced the publication of positive results from an in vivo study employing its OligoPhore technology in Adult T-cell Leukemia-Lymphoma (ATLL).

* The article was published in Nanomaterials, an international peer-reviewed open-access journal.

* Data demonstrated significant inhibition of tumor growth by siRNA knock-down of NF-?B utilizing the OligoPhore platform.

* The study demonstrated rapid delivery of siRNA to the tumor and significant reduction of target mRNA and protein expression, which altered the natural history of subsequent tumor progression.

* Tumor size, spleen size, and peripheral blood lymphocyte counts were significantly lower in treated mice than controls.

* Tumor growth was reduced to near zero in the most aggressive tumors.

* Further, the siRNA nanoparticles sensitized late-stage ATLL tumors to conventional chemotherapy with etoposide.

* ATLL is a rare and aggressive type of non-Hodgkin's lymphoma of mature T cells caused by the Human T-cell Leukemia / Lymphotropic Virus type 1 (HTLV 1).

* Price Action: EARS shares are up 12% at $3.72 during the market trading session on the last check Monday.